Discover
LBRX
LB Pharmaceuticals Inc Common Stock
45.85
1 x 42.77
1 x 54.27
bid
ask
-
2.15
4.48%
undefined @ 04:00 PM
46.76 +0.91 (1.98%)
| Ytd | 105.97% | |
| 1y | 165.03% |
44.00
day range
48.94
13.36
52 week range
49.14
| Open | 47.68 | Prev Close | 48.00 | Low | 44.00 | High | 48.94 | Mkt Cap | 1.31B |
| Vol | 422.68K | Avg Vol | 299.14K | EPS | -1.73 | P/E | -26.50 | Forward P/E | -11.47 |
| Beta | N/A | Short Ratio | 11.99 | Inst. Own | 109.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 33.10 | 200-d Avg | 25.53 | 1yr Est | 45.88 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-06-25 | 2026-06 | -0.8 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.75 | -0.67 | 0.08 | 10.67% |
| 2026-03-26 | 2025-12 | -0.45 | -0.45 | N/A | N/A |
| 2025-11-06 | 2025-09 | -0.57 | -0.61 | -0.04 | -7.02% |
| 2025-09-08 | 2025-06 | 0 | -1.44 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-21 | BMO Capital | Upgrade | Outperform | |
| 2026-07-07 | Wolfe Research | Upgrade | Outperform | |
| 2026-04-27 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-04-10 | Craig-Hallum | Upgrade | Buy | |
| 2026-03-27 | Stifel | Upgrade | Buy | Buy |
Profile
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-09-11 | DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | NUSSBAUM RAN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Deep Track Capital, Lp | 3.35M | 160.93M | 11.69% |
| 2026-06-29 | Blackrock Inc. | 2.73M | 131.25M | 9.53% |
| 2026-03-30 | RA Capital Management, L.P. | 2.21M | 106.01M | 7.70% |
| 2026-03-30 | TCG Crossover Management, LLC | 1.84M | 88.30M | 6.41% |
| 2026-03-30 | Commodore Capital Lp | 1.50M | 72.00M | 5.23% |
| 2026-03-30 | Caligan Partners, LP | 1.44M | 69.03M | 5.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 729.32K | 35.01M | 2.54% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 599.10K | 28.76M | 2.09% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 585.22K | 28.09M | 2.04% |
| 2026-05-30 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 567.63K | 27.25M | 1.98% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 274.12K | 13.16M | 0.96% |
| 2026-03-30 | JPMorgan Trust I-JPMorgan Small Cap Blend Fund | 235.45K | 11.30M | 0.82% |